Expanding its preclinical attack on Duchenne MD, Sarepta grabs a license for Duke's CRISPR tech
Sarepta $SRPT announced this morning that it’s teaming up with Duke University to explore new CRISPR-based methods in the hunt for an effective Duchenne muscular dystrophy therapy.
The company says it’s specifically interested in DMD, the rare and lethal condition it aimed to treat with its drug Exondys51. But remember, Sarepta got a controversial regulatory approval for Exondys51 based on data critics say never met a proper threshold for efficacy, and which they argue led the FDA to an erroneous conclusion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.